SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on March 13, 2003; DOI 10.1182/blood-2003-01-0025. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-01-0025v1 102/1/83    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Cortes, J. Articles by Kantarjian, H. Search for Related Content PubMed PubMed Citation Articles by Cortes, J. Articles by Kantarjian, H. Related Collections Neoplasia Oncogenes and Tumor Suppressors Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, 1 July 2003, Vol. 102, No. 1, pp. 83-86 CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Result of high-dose imatinib mesylate in patients with Philadelphia chromosome—positive chronic myeloid leukemia after failure of interferon- Jorge Cortes, Francis Giles, Susan O'Brien, Deborah Thomas, Guillermo Garcia-Manero, Mary Beth Rios, Stefan Faderl, Srdan Verstovsek, Alessandra Ferrajoli, Emil J. Freireich, Moshe Talpaz, and Hagop Kantarjian From the Department of Leukemia and Bioimmunotherapy, University of Texas, M. D. Anderson Cancer Center, Houston, TX. Imatinib at 400 mg daily is effective in chronic-phase chronic myeloid leukemia (CML) after interferon failure, although only a few patients achieve a molecular remission. We investigated whether higher doses of imatinib may be more effective. Thirty-six patients with chronic-phase CML after failure on interferon- were treated with 400 mg imatinib twice daily. Median time from diagnosis was 25 months (range, 10-135 months); 4 patients (11%) had clonal evolution. All 11 patients with active disease achieved complete hematologic response. Excluding patients with fewer than 35% Ph-positive metaphases before the start of therapy, 19 (90%) of 21 evaluable patients achieved a major cytogenetic response. Of 27 evaluable patients, 24 (89%) achieved a complete cytogenetic response. Quantitative polymerase chain reaction was performed in bone marrow every 3 months. Of 32 evaluable patients, 18 (56%) showed BCR-ABL/ABL percentage ratios lower than 0.045%, including 13 (41%) with undetectable levels. With a median follow-up of 15 months, all patients were alive in chronic phase. Toxicities were similar to those reported with standard dose; 71% of patients continue to receive 600 mg or more of imatinib daily. In conclusion, high-dose imatinib induces complete cytogenetic responses in most patients with chronic-phase CML after interferon failure. This is accompanied by a high rate of molecular remission. (Blood. 2003;102:83-86) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. D. Press, C. Galderisi, R. Yang, C. Rempfer, S. G. Willis, M. J. Mauro, B. J. Druker, and M. W.N. Deininger A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response Clin. Cancer Res., October 15, 2007; 13(20): 6136 - 6143. [Abstract] [Full Text] [PDF] V. G. Oehler, T. Gooley, D. S. Snyder, L. Johnston, A. Lin, C. C. Cummings, S. Chu, R. Bhatia, S. J. Forman, R. S. Negrin, et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia Blood, February 15, 2007; 109(4): 1782 - 1789. [Abstract] [Full Text] [PDF] M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet Blood, September 15, 2006; 108(6): 1809 - 1820. [Abstract] [Full Text] [PDF] P. Ault, H. Kantarjian, S. O'Brien, S. Faderl, M. Beran, M. B. Rios, C. Koller, F. Giles, M. Keating, M. Talpaz, et al. Pregnancy Among Patients With Chronic Myeloid Leukemia Treated With Imatinib J. Clin. Oncol., March 1, 2006; 24(7): 1204 - 1208. [Abstract] [Full Text] [PDF] G. Martinelli, I. Iacobucci, G. Rosti, F. Pane, M. Amabile, F. Castagnetti, D. Cilloni, S. Soverini, N. Testoni, G. Specchia, et al. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients Ann. Onc., March 1, 2006; 17(3): 495 - 502. [Abstract] [Full Text] [PDF] S. Kimura, H. Naito, H. Segawa, J. Kuroda, T. Yuasa, K. Sato, A. Yokota, Y. Kamitsuji, E. Kawata, E. Ashihara, et al. NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia Blood, December 1, 2005; 106(12): 3948 - 3954. [Abstract] [Full Text] [PDF] J. Cortes, M. Talpaz, S. O'Brien, D. Jones, R. Luthra, J. Shan, F. Giles, S. Faderl, S. Verstovsek, G. Garcia-Manero, et al. Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate Clin. Cancer Res., May 1, 2005; 11(9): 3425 - 3432. [Abstract] [Full Text] [PDF] M. Deininger, E. Buchdunger, and B. J. Druker The development of imatinib as a therapeutic agent for chronic myeloid leukemia Blood, April 1, 2005; 105(7): 2640 - 2653. [Abstract] [Full Text] [PDF] A. Quintas-Cardama, H. Kantarjian, M. Talpaz, S. O'Brien, G. Garcia-Manero, S. Verstovsek, M. B. Rios, K. Hayes, A. Glassman, B. N. Bekele, et al. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia Blood, March 15, 2005; 105(6): 2281 - 2286. [Abstract] [Full Text] [PDF] M. W.N. Deininger Management of Early Stage Disease Hematology, January 1, 2005; 2005(1): 174 - 182. [Abstract] [Full Text] [PDF] M. A. Champagne, R. Capdeville, M. Krailo, W. Qu, B. Peng, M. Rosamilia, M. Therrien, U. Zoellner, S. M. Blaney, and M. Bernstein Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study Blood, November 1, 2004; 104(9): 2655 - 2660. [Abstract] [Full Text] [PDF] M. Harata, Y. Soda, K. Tani, J. Ooi, T. Takizawa, M. Chen, Y. Bai, K. Izawa, S. Kobayashi, A. Tomonari, et al. CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells Blood, September 1, 2004; 104(5): 1442 - 1449. [Abstract] [Full Text] [PDF] R. M. Stone Optimizing Treatment of Chronic Myeloid Leukemia: A Rational Approach Oncologist, June 1, 2004; 9(3): 259 - 270. [Abstract] [Full Text] [PDF] F. Guilhot Indications for Imatinib Mesylate Therapy and Clinical Management Oncologist, June 1, 2004; 9(3): 271 - 281. [Abstract] [Full Text] [PDF] H. Kantarjian, M. Talpaz, S. O'Brien, G. Garcia-Manero, S. Verstovsek, F. Giles, M. B. Rios, J. Shan, L. Letvak, D. Thomas, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia Blood, April 15, 2004; 103(8): 2873 - 2878. [Abstract] [Full Text] [PDF] G. Rosti, G. Martinelli, S. Bassi, M. Amabile, E. Trabacchi, B. Giannini, D. Cilloni, B. Izzo, A. De Vivo, N. Testoni, et al. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia Blood, March 15, 2004; 103(6): 2284 - 2290. [Abstract] [Full Text] [PDF] A. D. Klion, J. Robyn, C. Akin, P. Noel, M. Brown, M. Law, D. D. Metcalfe, C. Dunbar, and T. B. Nutman Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome Blood, January 15, 2004; 103(2): 473 - 478. [Abstract] [Full Text] [PDF] M. Gardembas, P. Rousselot, M. Tulliez, M. Vigier, A. Buzyn, F. Rigal-Huguet, L. Legros, M. Michallet, C. Berthou, N. Cheron, et al. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase Blood, December 15, 2003; 102(13): 4298 - 4305. [Abstract] [Full Text] [PDF] D. Marin, J. M. Goldman, E. Olavarria, J. F. Apperley, J. Cortes, and H. Kantarjian Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses Blood, October 1, 2003; 102(7): 2702 - 2703. [Full Text] [PDF] J. V. Melo, T. P. Hughes, and J. F. Apperley Chronic Myeloid Leukemia Hematology, January 1, 2003; 2003(1): 132 - 152. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020